Multiple ALK inhibitors have since then been developed, including crizotinib, a tyrosine kinase inhibitor (TKI) approved by the US Food and Drug Administration (FDA) in 2011 and indicated for ALK-positive NSCLC [9]. Here, ALK is linked to non-small cell lung carcinoma.